← Eichor
Study identifier: NCT05405868 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial

Condition: Glaucoma, Open-Angle  ·  Sponsor: University College, London

PhasePhase 3
Planned participants496
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Glaucoma is the leading cause of sight impairment and blindness worldwide. It is a long-term eye disease which can cause permanent loss of sight and sometimes blindness and affects 1 in 50 people over 50 years of age. Open-angle glaucoma (OAG) is the most common type of glaucoma. This tends to develop slowly over many years, caused by the drainage pathway in the eye gradually becoming blocked over time due to a build-up of fluid. This build-up causes pressure in the eye to increase (intra-ocular pressure (IOP)), which then damages the important nerve at the back of the eye called the optic nerve, resulting in vision loss. Current treatments offered for glaucoma (eye drops or laser surgery), aim to lower eye pressure and have shown to slow vision loss, however, visual disability and blindness rates remain unacceptably high and many patients continue to lose vision despite these treatments, suggesting that the optic nerve in some patients is more easily damaged. Recent research has looked at cells called 'mitochondria'. These cells produce most of the energy in the body, and the nerve cells in the eye need a lot of energy to function and survive. Nicotinamide (NAM) is a form of Vitamin B3 and evidence so far has shown that mitochondrial function can be improved with this treatment. The aim of this trial is to find out whether taking oral NAM when used with current standard treatment for lowering pressure in the eye, can reduce the amount of sight loss in recently diagnosed pati…

This description comes directly from the study's public registry record.

Talk to the study team

NAMinG Trial Team  ·  0203 108 6148  ·  cctu.naming@ucl.ac.uk

Felicia Ikeji  ·  020 7679 9506  ·  f.ikeji@ucl.ac.uk

Always discuss trial participation with your own doctor first.

Locations (10)

Belfast City HospitalBelfast, Northern Ireland, United KingdomNot Yet Recruiting
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation TrustCambridge, United KingdomNot Yet Recruiting
Queen Victoria Hospital NHS Foundation TrustEast Grinstead, United KingdomRecruiting
Royal Liverpool HospitalLiverpool, United KingdomNot Yet Recruiting
Moorfields Eye Hospital NHS Foundation TrustLondon, United KingdomRecruiting
Barnet Hospital, Royal Free London NHS Foundation TrustLondon, United KingdomNot Yet Recruiting
King's College Hospital NHS Foundation TrustLondon, United KingdomRecruiting
Manchester Royal Eye HospitalManchester, United KingdomNot Yet Recruiting
Nottingham University Hospitals NHS TrustNottingham, United KingdomNot Yet Recruiting
Queen Alexandra HospitalPortsmouth, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05405868